Yan Ran, Cui Weitong, Ma Wenjuan, Li Jiajie, Liu Zhiqiang, Lin Yunfeng
State Key Laboratory of Oral Diseases, National Clinical Research Centre for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P. R. China.
Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China.
ACS Nano. 2023 May 9;17(9):8767-8781. doi: 10.1021/acsnano.3c02102. Epub 2023 Apr 14.
Acute kidney injury (AKI) is not only a worldwide problem with a cruel hospital mortality rate but also an independent risk factor for chronic kidney disease and a promoting factor for its progression. Despite supportive therapeutic measures, there is no effective treatment for AKI. This study employs tetrahedral framework nucleic acid (tFNA) as a vehicle and combines typhaneoside (Typ) to develop the tFNA-Typ complex (TTC) for treating AKI. With the precise targeting ability on mitochondria and renal tubule, increased antiapoptotic and antioxidative effect, and promoted mitochondria and kidney function restoration, the TTC represents a promising nanomedicine for AKI treatment. Overall, this study has developed a dual-targeted nanoparticle with enhanced therapeutic effects on AKI and could have critical clinical applications in the future.
急性肾损伤（AKI）不仅是一个全球范围内存在的问题，有着残酷的医院死亡率，而且是慢性肾脏病的独立危险因素及其进展的促进因素。尽管有支持性治疗措施，但目前尚无针对AKI的有效治疗方法。本研究采用四面体框架核酸（tFNA）作为载体，并结合巴戟天苷（Typ）来开发用于治疗AKI的tFNA-Typ复合物（TTC）。由于TTC对线粒体和肾小管具有精确的靶向能力、增强的抗凋亡和抗氧化作用以及促进线粒体和肾功能恢复，它是一种很有前景的用于治疗AKI的纳米药物。总体而言，本研究开发了一种对AKI具有增强治疗效果的双靶向纳米颗粒，未来可能具有关键的临床应用价值。
